EP3426284 - Bibliographic data
AGONISTE DU GLP-1/GLUCAGON POUR L'UTILISATION DANS LE TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE
| Last update | 02/06/2025 |
|---|---|
| Legal status | Brevet délivré |
| Origin | Euro-PCT |
| (73) Holder |
MedImmune Limited 1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
Royaume-Uni
|
|---|---|
| (72) Inventors |
Maria BEDNAREK MedImmune Limited Milstein Building
Granta Park
Cambridge
Cambridgeshire CB21 6GH
Royaume-Uni
Lutz JERMUTUS Milstein Building Granta Park
Cambridge
Cambridgeshire CB21 6GH
Royaume-Uni
Philip AMBERY Milstein Building Granta Park
Cambridge
Cambridgeshire CB21 6GH
Royaume-Uni
Marcella PETRONE Milstein Building Granta Park
Cambridge
Cambridgeshire CB21 6GH
Royaume-Uni
|
| (74) Agent |
Mail recipient AstraZeneca Intellectual Property Eastbrook House
Shaftesbury Road
Cambridge CB2 8BF
Royaume-Uni
|
| (21) Request number | EP17710231.6 |
|---|---|
| (22) Request date | 10/03/2017 |
| (11) Publication number | EP3426284 |
|---|---|
| Publication date | 08/05/2024 |
| (54) Title of the invention | AGONISTE DU GLP-1/GLUCAGON POUR L'UTILISATION DANS LE TRAITEMENT DE LA STÉATOHÉPATITE NON ALCOOLIQUE |
|---|---|
| (51) International classification | A61K 38/26, A61P 3/04, A61P 3/06, A61P 3/10, A61P 9/12 |
| International classification (before reform) | None |
| Claimed priority |
(31) Number: 201662306121 P |
|---|---|
| Initial application | None |
| Divisional application | None |
| Expected annuity |
Annuity: 9 -
Amount: 175 € -
Due date 31/03/2025
Surtax: 9 - Amount: 35 € - Due date 01/10/2025 |
|---|---|
| Last annuity | None |
| Publication | None |
|---|---|
| History | Publication de la délivrance du brevet européen - Legal date 08/05/2024 Entrée en période de grâce du brevet d'invention - Legal date 01/04/2025 |